Article info

Role of the selective cyclo-oxygenase-2 (COX-2) inhibitors in children
Free
  1. Correspondence to:
    MrSean Turner
    Clinical Services, Princess Margaret Hospital, Roberts Road, Perth, Western Australia 6008, Australia; sean.turner{at}health.wa.gov.au
View Full Text

Citation

Turner S, Ford V
Role of the selective cyclo-oxygenase-2 (COX-2) inhibitors in children

Publication history

  • First published September 22, 2004.
Online issue publication 
September 22, 2004
  • Worldwide withdrawal of Vioxx (rofecoxib; Merck)

    One of the selective COX-2 inhibitors mentioned in this article (Vioxx (Rofecoxib; Merck)) has been voluntarily withdrawn by the manufacturer because of an increased relative risk for cardiovascular events, such as heart attack and stroke based on new, three-year data from a prospective, randomized, placebo-controlled clinical trial, the APPROVe (Adenomatous Polyp Prevention on VIOXX) trial.

    A press release issued by Merck is available online at http://www.merck.com/newsroom/press_releases/product/2004_0930.html

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.